Subject Area and Research Team: II. Tumour microenvironment, microbiome ...

Subject Area and Research Team: II. Tumour microenvironment, microbiome and immunooncology


Research topics

1. Determination of factors predictive for safe and efficient CAR-T cell therapy

2. Analysis of immune cell subsets and their activation status for prediction of clinical outcome and treatment selection

3. Microenvironmental and genetic factors contributing to oncogenesis, resistance to cancer therapy and metastasis

4. Tumour-immune system cross talk and cancer immune evasion

5. Immune senescence, chemotherapy and gut microbiome – their interplay and impact on anti-cancer immune response

Coordinators

Coordinator #1 Coordinator #2
Name and surname
prof._Natalia_Marek-Trzonkowska.jpg
Natalia Marek-Trzonkowska
Karol_Połom.jpg
Karol Połom
Academic degree Prof. Dr. Habil. Dr. Habil.
Employment unit Department Family Medicine Department of Oncologic Surgery
Polish Platform of Medical Research Prof. Dr. Habil. Natalia Marek-Trzonkowska Dr. Habil. Karol Połom
Email natalia.marek@gumed.edu.pl karol.polom@gumed.edu.pl
Phone number +48 58 349 15 75
+48 58 523 34 64
+48 58 349 31 90

photos Paweł Sudara/MUG


Research Team: II. Tumour microenvironment, microbiome and immunooncology

Team Members: II. Tumour microenvironment, microbiome and immunooncology (190 KB)


Feel free to contact one of our coordinators to join our Research Team.

Key current projects

1. Tumour-stroma crosstalk in tumour dissemination and metastasis formation

2. Cancer immunescape

3. Cellular therapy of non-small cell lung cancer

4. Genetic features of Reed-Sternberg cells and their interplay with immune system in Hodgkin lymphoma

5. Prognostic value of intratumoural stromal cells in prostate cancer

Key grants

Funding agency/grant number Title of the project Years
1. Medical Research Agency/ RAFTING-2019/ 2019/ABM/01/00060 Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumour volume and a negative interim PET after 2 chemotherapy cycles 2021-2026
2. National Science Centre (NCN), Sonata Bis, no. 2018/30/E/NZ3/00222 „FGFR2-triggered signalling in regulation of ER/PR interdependence – molecular mechanism and predictive value for patients with luminal A breast cancer” (2 499 000 PLN) 2019-2024
3. National Science Centre (NCN), Sonata no. 2017/26/D/NZ5/01088 “Molecular and clinical characterization of keratin-based phenotypes in prostate cancer” 2018-2022

International cooperation

Foreign partner (unit name) Principal investigator(s) Area of cooperation
1. Laboratory of Pathology, National Cancer Institute (NCI), Bethesda, Maryland, USA Jerzy Lasota Signalling pathways in head and neck cancer
2. Research Centre on Aging, Graduate Programme in Immunology, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, Quebec, Canada Tamas Fulop Mechanisms of immunosenescence and their role in cancer pathogenesis
3. University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, Scotland, United Kingdom Ted Hupp Neoantigen science, receptors at the cancer-immune synapse, proteogenomic and computational science
4. Institute of Oncology Research, Bellinzona, Switzerland Davide Rossi Hodgkin lymphoma
5. Department of Pathology, University of Regensburg Christoph Klein Single cell profiling
POB_1__RT_2.png

Key publications

1. Chruściel E, Urban-Wójciuk Z, Arcimowicz Ł, Kurkowiak M, Kowalski J, Gliwiński M, Marjański T, Rzyman W, Biernat W, Dziadziuszko R, Montesano C, Bernardini R, Marek-Trzonkowska N. Adoptive Cell Therapy-Harnessing Antigen-Specific T Cells to Target Solid Tumours. Cancers (Basel) 2020; vol. 12: p. 683.

2. Szydlowski M, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Derezińska E, Hoser G, Wasilewska D, Szymańska-Giemza O, Jabłońska E, Białopiotrowicz E, Sewastianik T, Polak A, Czardybon W, Gałęzowski M, Windak R, Zaucha JM, Warzocha K, Brzózka K, Juszczyński P. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. Blood. 2017; vol. 130: p. 1418-1429.

3. He Y, Zhang X, Jia K, Dziadziuszko R, Zhao S, Deng J, Wang H, Hirsch FR, Zhou C. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Transl Lung Cancer Res. 2019; vol. 8: p. 352-366.

4. Markiewicz A, Topa J, Nagel A, Skokowski J, Seroczynska B, Stokowy T, Welnicka-Jaskiewicz M, Zaczek AJ. Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients. Cancers. 2019; vol. 11(1): p. 59.

5. Piasecka D, Braun M, Kitowska K, Mieczkowski K , Kordek R, Sadej R, Romanska H. FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors – implications for therapy of luminal breast cancer. J Exp Clin Cancer Res. 2019; vol. 38: p. 230.